The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands

M. D. Filipe1 · S. Siesling2,3 · M. R. Vriens1 · P. van Diest4 · A. J. Witkamp1

Received: 3 February 2021 / Accepted: 20 June 2021 / Published online: 26 June 2021
© The Author(s) 2021

Abstract

Background Previous studies have shown that socioeconomic status (SES) influences breast cancer therapy. However, these studies were performed in countries with unequal access to healthcare. Therefore, the aim of this study is to investigate whether SES also contributes to the likelihood of receiving a certain therapy in the Netherlands, a country with supposedly equal access to healthcare.

Materials and methods From the Netherlands Cancer Registry, 105,287 patients with newly diagnosed stage I or II breast cancer diagnosed between 2011 and 2018 were selected for analysis. SES was calculated from the average incomes of each postal code, which were divided into 10 deciles. Primary outcome was the effect of SES on the likelihood of undergoing surgery and secondary outcome was the effect of SES on the likelihood of the type of surgery. Both outcomes were corrected for patient, tumor, and hospital characteristics and were expressed as odds ratio (OR) with 95% confidence interval (CI).

Results SES did not affect the likelihood of a breast cancer patient to undergo surgery (OR 1.00 per 10% stratum). In contrast, increased age and higher tumor stage were the most important factors determining whether patients underwent surgery. Patients with higher SES were less likely to undergo mastectomy (OR 0.98). Additionally, more recently diagnosed patients were less likely to undergo mastectomy (OR 0.93 per year) while patients with higher tumor stage were more likely to undergo mastectomy (OR 3.42).

Conclusion SES does not affect whether a patient undergoes surgery; however, higher SES increased the likelihood of BCT.

Keywords Socioeconomic status · Cancer registry · Population-based study

Introduction

Breast cancer is the most common cancer in women and the second most common cause of death due to cancer in women worldwide [1]. There are roughly 17,000 new cases of breast cancer in the Netherlands every year. Additionally, over 3000 people of the Dutch population die annually due to breast cancer [2, 3].

Surgical resection of the primary tumor is the treatment of choice in patients with newly diagnosed breast cancer. Tumor stage and molecular characteristics determine the type of surgery. The main types of surgery for stages I and II are mastectomy and breast-conserving therapy (BCT) [4–6]. In the Netherlands, the percentage BCT is about 65% and this has been shown to differ between regions [7]. Reasons for these differences can be the preference of the clinician, age of patient, tumor grade, tumor stage, and hormone receptor status [7]. Moreover, socioeconomic status (SES)
might be of influence here since it is not equally spread over the country [8].

SES is a complex classification system to stratify economic and social factors [9]. SES has shown to be of influence the incidence and severity of diseases. Low SES is associated with a higher incidence of lifestyle related risk factors, such as smoking, higher BMI, and drug use [10]. This high risk behavior leads to an increased risk for the development of disease, such as diabetes, cardiovascular disease, psychiatric disorders, and numerous types of cancer [10–14].

Differences in treatment between SES classes have been described in a systematic review in which patients with breast cancer who, among other factors, had a higher SES were more likely to undergo BCT [15]. Additionally, in the United States of America unequal access to healthcare due to financial barriers leads to therapeutic choices based on income [16]. Various studies in the United States showed that SES influences the choice for the surgical procedure [17, 18]. Furthermore, a Danish study showed that low SES stage I or II breast cancer patients tended to have more mastectomies despite equal access to healthcare. There was no clear explanation for this disparity [19]. However, this was not a population-based cohort, and the study cohort was closed 1998 while treatment options have changed since then.

In the Netherlands, there is universal healthcare which means that citizens do not have financial barriers when requesting medical attention [16]. Additionally, the compulsory insurance covers almost all costs for hospitals and primary care [16, 20].

Currently, no studies have analyzed the influence of SES on treatment choices and type of surgery in patients with stage I and II breast cancer where there are no financial barriers to healthcare. The aim of this study was therefore to determine whether SES influences the treatment of stage I and II breast cancer in the Netherlands since there are no barriers for access to healthcare.

Definitions
The NCR contains patient, tumor, and treatment characteristics. Tumors are categorized according to the tumor, node, and metastasis (TNM) classification system [21]. Due to changes in the N1 category from the 5th to the 6th editions of the International Classification of Diseases for Oncology, we classified the number of positive lymph into N categories. Patients without lymph node involvement were classified as N0 and patients with 1 to 3 positive lymph nodes were classified as N1. TNM was converted to tumor stage (stage I or stage II). Histological subtype consisted of lobular, ductal, mucinous, medullary tubular, or not specified [22]. Tumor grade was divided into low grade, intermediate grade, and high grade [23].

SES was determined using the average income of a household according to the four-digit postal code in the Netherlands at time of diagnosis and surgical procedure, and was defined according to the Dutch Bureau of Statistics (CBS) [24]. Furthermore, the average incomes of each postal code were divided into 10 deciles. Additionally, hospital volume was stratified based on the number of breast cancer patients treated per year: low volume (< 100), medium volume (100–149), and high volume (> 150), as described in previous studies [25].

Outcomes
Primary outcome was the effect of SES on the likelihood of a new-onset breast cancer patients undergoing surgery versus no surgical treatment. Secondary outcome was determining the effect of SES on type of surgery (BCT or mastectomy). Both outcomes were determined after correcting for patient, tumor, and hospital characteristics.

Statistics
Descriptive statistics were used to describe patient, tumor, and treatment characteristics. Continuous data were described with mean along with standard deviation (SD), or with median and interquartile range (IQR), depending on whether or not the data were normally distributed. Mann–Whitney U tests or Student’s t tests were used to test differences between groups of not normally and normally distributed continuous data, respectively. Differences between categorical data were analyzed with Chi-Square or Fisher’s exact tests.

Since some data were missing during the study period, multiple imputation by chained equations (MICE) was performed using the MICE package in R. After comparing and correlating the missing to the non-missing data,
it was concluded that the values were missing at random. The imputation was repeated 20 times, followed by application of Rubin’s rule to combine parameter estimates and standard errors [26, 27]. Imputed data were later compared to the complete cases to determine validity of the imputation model. Subsequently, the imputed data were used for analyses.

Multivariable regression analyses were performed to study the association between SES and the likelihood [quantified in odds ratio (OR) and 95% confidence interval (CI)] of undergoing a certain treatment strategy (no surgery vs. surgery, and BCT vs. mastectomy) in patients with stage I or II breast cancer. Possible confounding factors and effect modifiers considered were age at diagnosis, stage (1 or 2) and co-morbidities. Two-sided P values below 0.05 were considered statistically significant.

All calculations were performed using RStudio 1.2.5001 (with R version: × 64 3.6.3). Visualization of plots was performed using the ggplot2 package.

**Results**

Between 2011 and 2018, 105,287 patients had new-onset stage I or II breast cancer, of whom 6840 patients (6.5%) did not undergo surgery. Furthermore, 98,447 stage I or II breast cancer patients underwent surgery of whom 65,888 patients underwent BCT and 32,559 patients had undergone mastectomy suitable for analysis.

Table 1 shows the baseline characteristics of all 105,287 stage I or II breast cancer patients suitable for analysis. Mean age was 62.0 years. The national screening program detected breast cancer in 39,094 (37.7%) patients and 393 (0.4%) patients had a positive oncological history other than breast cancer. A total of 98,447 (93.5%) stage I or II breast cancer patients underwent surgery (BCT or mastectomy), while 6840 (6.5%) breast cancer patients had no surgery but were treated with only chemotherapy, hormone therapy, and/or radiotherapy. The proportion of breast cancer patients undergoing non-surgical treatment slightly increased over time (Fig. 1). Stage I or II breast cancer was evenly spread among the different strata of SES. The proportion of BCT substantially increases, while the proportion mastectomies decreases.

Table 2 shows the different characteristics of patients stratified for surgery-or-not. Patients not undergoing surgery were significantly older, and more often of higher stage and grade, and more often had HER2-negative and estrogen receptor-positive tumors. Furthermore, patients undergoing surgery were more often triple negative (3.8%) compared to patients not undergoing surgery (1.8%). 9465 (91.2%) of the patients with the lowest SES underwent surgery which was significantly less than the 10,590 (94.7%) of the patients with the highest SES. However, after correcting for patient and tumor characteristics in multivariable analysis, SES was no predictor for undergoing surgery, while age, triple-negative receptor status, and tumor stage (highest absolute z value) played the most important role in determining surgery-or-not (Table 3).

Stratified by type of breast cancer surgery (Table 4) patients who underwent mastectomy were slightly, but significantly, older and had lower SES. Additionally, patients with lower tumor stage more often received BCT. Furthermore, patients undergoing mastectomy were more often HER2-negative and estrogen receptor-positive compared to BCT counterparts. Moreover, increasing tumor grade and

---

**Table 1 Baseline characteristics of all new-onset breast cancer patients diagnosed in the Netherlands between 2011 and 2018**

| Characteristic                                      | N=105,287 |
|-----------------------------------------------------|-----------|
| Age in years, mean (SD)                             | 62.0 (13.5) |
| Age groups                                          |           |
| Under 40 years, N (%)                               | 4494 (4.3%) |
| 40–50 years, N (%)                                  | 15,584 (14.9%) |
| 50–75 years, N (%)                                  | 66,735 (63.6%) |
| Over 75 years, N (%)                                | 18,106 (17.3%) |
| Affected side                                       |           |
| Left, N (%)                                         | 53,379 (50.9%) |
| Right, N (%)                                        | 51,540 (49.1%) |
| Medical history                                     |           |
| No medical history, N (%)                           | 95,874 (92.9%) |
| Positive non-oncological medical history, N (%)     | 6885 (6.7%) |
| Positive oncological medical history, N (%)         | 393 (0.4%) |
| Detected by national screening program, N (%)       | 39,094 (37.7%) |
| Type of treatment                                   |           |
| No surgery, N (%)                                   | 6805 (6.5%) |
| BCT, N (%)                                          | 65,704 (62.6%) |
| Mastectomy, N (%)                                   | 32,410 (30.9%) |
| Tumor stage                                         |           |
| Stage I, N (%)                                      | 61,011 (58.2%) |
| Stage II, N (%)                                     | 43,908 (41.8%) |
| Socioeconomic status                                |           |
| 0–9%, N (%)                                         | 10,349 (9.9%) |
| 10–20%, N (%)                                       | 10,428 (9.9%) |
| 20–30%, N (%)                                       | 10,274 (9.8%) |
| 30–40%, N (%)                                       | 10,289 (9.8%) |
| 40–50%, N (%)                                       | 10,557 (10.1%) |
| 50–60%, N (%)                                       | 10,233 (9.8%) |
| 60–70%, N (%)                                       | 10,278 (9.8%) |
| 70–80%, N (%)                                       | 10,616 (10.1%) |
| 80–90%, N (%)                                       | 10,760 (10.3%) |
| 90–100%, N (%)                                      | 11,135 (10.6%) |

SD standard deviation, N number, BIRADS breast imaging reporting and data system, BCT breast-conserving therapy
triple-negative receptor status was associated to an increased likelihood of undergoing mastectomy. After correcting for patient and tumor characteristics, SES remained a significant predictor for type of surgery where breast cancer patients with higher SES were significantly more likely to undergo BCT (Table 5). Breast cancer patients with the lowest SES stratum have an OR of 0.81 (or 44.9% less likely) of undergoing BCT compared to the highest SES stratum.

Discussion

In this population-based study in a country where everyone has equal access to care, patients with newly diagnosed stage I or II breast cancer and patients with higher SES were significantly more likely to undergo BCT than mastectomy. SES did not affect whether or not patients underwent surgery or not, but older and higher tumor stage patients were less likely to undergo a surgical procedure. Furthermore, more BCT and fewer mastectomies are performed as the years go by.

The current study shows that for newly diagnosed stage I or II breast cancer patients, the higher the SES, the more likely it is that patients will undergo BCT, even in a country with equal access to care. This is in line with previous studies, regardless of whether there is universal healthcare or not [17–19]. Additionally, hospital with a lower breast cancer treatment volume was less likely to perform BCT. This is in line with previous studies which reported that hospital volume affects different aspects of breast cancer treatment [7, 28]. Additionally, reasons for these differences can be the preference of the clinician, unequal spread of SES within the Netherlands, age of patient, tumor grade, tumor stage, and hormone receptor status [7, 8]. Furthermore, a recent study showed that breast cancer patients with high SES are more likely to undergo postmastectomy reconstruction than their lower SES counterparts [29].

The finding that SES did not play a role in whether or not patients underwent surgery is in contrast with countries with no universal healthcare systems, in which therapeutic choices are heavily influenced by income and health care insurance system [17, 18]. Age being the most important factor determining whether a patient underwent...
| Parameter                                                                 | No surgery $n=6,840$ | Surgery $n=98,447$ | $p$ value |
|--------------------------------------------------------------------------|---------------------|--------------------|-----------|
| Age in years, mean (SD)                                                  | 82.1 (11.1)         | 60.6 (12.6)        | <0.001    |
| Age groups                                                               |                     |                    | <0.001    |
| Under 40 years, $N$ (%)                                                 | 50 (1.1%)           | 4476 (98.9%)       |           |
| 40–50 years, $N$ (%)                                                     | 139 (0.9%)          | 15,538 (99.1%)     |           |
| 50–75 years, $N$ (%)                                                     | 907 (1.4%)          | 66,013 (98.6%)     |           |
| Over 75 years, $N$ (%)                                                  | 5744 (31.6%)        | 12,420 (68.4%)     |           |
| Detected during screening, $N$ (%)                                       | 233 (3.4%)          | 39,370 (40.0%)     | <0.001    |
| Socioeconomic status                                                    |                     |                    | <0.001    |
| 0–9%, $N$ (%)                                                            | 917 (8.8%)          | 9465 (91.2%)       |           |
| 10–20%, $N$ (%)                                                          | 774 (7.4%)          | 9700 (92.6%)       |           |
| 20–30%, $N$ (%)                                                          | 717 (7.0%)          | 9588 (93.0%)       |           |
| 30–40%, $N$ (%)                                                          | 665 (6.4%)          | 9662 (93.6%)       |           |
| 40–50%, $N$ (%)                                                          | 675 (6.4%)          | 9912 (93.6%)       |           |
| 50–60%, $N$ (%)                                                          | 685 (6.7%)          | 9587 (93.3%)       |           |
| 60–70%, $N$ (%)                                                          | 623 (6.0%)          | 9688 (94.0%)       |           |
| 70–80%, $N$ (%)                                                          | 594 (5.6%)          | 10,056 (94.4%)     |           |
| 80–90%, $N$ (%)                                                          | 595 (5.5%)          | 10,199 (94.5%)     |           |
| 90–100%, $N$ (%)                                                         | 595 (5.3%)          | 10,590 (94.7%)     |           |
| Tumor stage                                                              |                     |                    | <0.001    |
| Stage I, $N$ (%)                                                         | 2394 (3.9%)         | 58,617 (96.1%)     |           |
| Stage II, $N$ (%)                                                        | 4446 (10.0%)        | 39,830 (90.0%)     |           |
| Medical history                                                          |                     |                    | <0.001    |
| No medical history, $N$ (%)                                              | 6562 (2.6%)         | 91,299 (97.4%)     |           |
| Positive non-oncological medical history, $N$ (%)                        | 247 (3.5%)          | 6774 (96.5%)       |           |
| Positive oncological medical history, $N$ (%)                            | 31 (0.5%)           | 374 (92.3%)        |           |
| Hormone receptor status                                                  |                     |                    | <0.001    |
| Her2 receptor negative, $N$ (%)                                          | 6331 (6.8%)         | 86,808 (93.2%)     | <0.001    |
| Progesterone receptor positive, $N$ (%)                                   | 4636 (6.5%)         | 66,854 (93.5%)     | 0.831     |
| Estrogen receptor positive, $N$ (%)                                      | 5820 (6.7%)         | 81,244 (93.3%)     | <0.001    |
| Triple negative                                                          | 128 (3.3%)          | 3757 (96.7%)       | <0.001    |
| Tumor grade                                                              |                     |                    | <0.001    |
| Low grade, $N$ (%)                                                       | 1910 (7.2%)         | 24,757 (92.8%)     |           |
| Intermediate grade, $N$ (%)                                              | 3505 (6.9%)         | 47,590 (93.1%)     |           |
| High grade, $N$ (%)                                                      | 1425 (5.2%)         | 26,100 (94.8%)     |           |
| Histological tumor type                                                  |                     |                    | <0.001    |
| No special type, $N$ (%)                                                 | 5198 (6.1%)         | 79,460 (93.9%)     |           |
| Lobular (ILC), $N$ (%)                                                   | 1072 (8.5%)         | 11,536 (91.5%)     |           |
| Both, $N$ (%)                                                            | 91 (2.9%)           | 3041 (97.1%)       |           |
| Mucinous, $N$ (%)                                                        | 300 (14.6%)         | 1756 (85.4%)       |           |
| Medullary, $N$ (%)                                                       | 10 (2.2%)           | 594 (99.8%)        |           |
| Tubular, $N$ (%)                                                         | 18 (2%)             | 898 (98.0%)        |           |
| Other, $N$ (%)                                                           | 160 (12.1%)         | 1162 (87.9%)       |           |
| Hospital volume                                                          |                     |                    | 0.395     |
| Low volume                                                               | 662 (6.7%)          | 9166 (93.3%)       |           |
| Average volume                                                           | 1649 (6.4%)         | 24,302 (93.6%)     |           |
| High volume                                                              | 4529 (6.5%)         | 64,979 (93.5%)     |           |
| Year of diagnosis                                                        |                     |                    | <0.001    |
| 2011, $N$ (%)                                                            | 792 (6.2%)          | 11,908 (93.8%)     |           |
| 2012, $N$ (%)                                                            | 798 (6.1%)          | 12,180 (93.9%)     |           |
| 2013, $N$ (%)                                                            | 800 (6.1%)          | 12,290 (93.9%)     |           |
| 2014, $N$ (%)                                                            | 833 (6.3%)          | 12,332 (93.7%)     |           |
| 2015, $N$ (%)                                                            | 815 (6.2%)          | 12,329 (93.8%)     |           |
| 2016, $N$ (%)                                                            | 870 (6.6%)          | 12,324 (93.4%)     |           |
| 2017, $N$ (%)                                                            | 961 (7.0%)          | 12,700 (93.0%)     |           |
| 2018, $N$ (%)                                                            | 971 (7.3%)          | 12,384 (92.7%)     |           |
surgery is probably related to the fact that older patients are more likely to have co-morbidities with a higher risk of postoperative complications, leading to surgery less often being advised [30, 31]. This could also explain why newly diagnosed stage I or II breast cancer patients who did not undergo surgery were significantly older than patients who did undergo surgery (over 20 years on average).

Over time, more BCT procedures but fewer mastectomies were performed. This is probably due to increasingly favoring BCT over mastectomy with its higher complication rate along with serious cosmetic and psychological consequences, while have similar overall survival [6, 32, 33].

The current study shows that for new-onset stage I or II breast cancer patients, the higher the SES, the more likely patients will undergo BCT. Furthermore, when adjusting for age, tumor characteristics, and medical history, these differences remain. The current study shows that even in a country with equal access to care, SES does play a role in whether a patient receives BCT or mastectomy despite there being no differences in (cancer-free) survival [6, 32, 33]. This is in line with previous studies, regardless of whether there is universal income or not [17–19]. The relation between hospital volume and immediate breast reconstruction could relate to organizational factors, such as the live attendance of a plastic surgeon to the multidisciplinary meetings, which is

---

**Table 2** (continued)

| Parameter                  | Estimate (β) | OR (95% CI)       | Standard error | Z value | p value |
|----------------------------|--------------|-------------------|----------------|---------|---------|
| SES (per 10% stratum)      | 0.010        | 1.01 (1.00–1.02)  | 0.005          | 1.877   | 0.060   |
| Age (years)                | −0.169       | 0.84 (0.84–0.85)  | 0.002          | −94.497 | <0.001  |
| Year of treatment          | −0.026       | 0.97 (0.96–0.99)  | 0.007          | −3.953  | <0.001  |

**Table 3** Multivariate regression analysis factors influencing non-surgical therapy versus surgery

| Parameter                  | Estimate (β) | OR (95% CI)       | Standard error | Z value | p value |
|----------------------------|--------------|-------------------|----------------|---------|---------|
| Hospital volume            |              |                   |                |         |         |
| Small volume               | NA           | 1.00 (reference)  | NA             | NA      | NA      |
| Average volume             | 0.010        | 1.01 (0.90–1.13)  | 0.058          | 0.172   | 0.863   |
| Large volume               | −0.101       | 0.90 (0.82–1.00)  | 0.053          | −1.916  | 0.055   |
| Tumor grade                |              |                   |                |         |         |
| Low grade                  | NA           | 1.00 (reference)  | NA             | NA      | NA      |
| Intermediate grade         | 0.092        | 1.1 (1.02–1.18)   | 0.038          | 2.439   | 0.015   |
| High grade                 | 0.375        | 1.45 (1.32–1.60)  | 0.049          | 7.700   | <0.001  |
| Histological subtype       |              |                   |                |         |         |
| Ductal carcinoma           | NA           | 1.00 (reference)  | NA             | NA      | NA      |
| ILC                        | −0.031       | 0.97 (0.89–1.05)  | 0.043          | −0.723  | 0.470   |
| Both                       | 0.697        | 2.01 (1.59–2.53)  | 0.119          | 5.859   | <0.001  |
| Mucinous                   | 0.232        | 1.26 (1.08–1.47)  | 0.078          | 2.964   | 0.003   |
| Medullary                  | 3.040        | 20.89 (2.92–149.49) | 1.004       | 3.028   | 0.002   |
| Tubular                    | 0.400        | 1.49 (0.90–2.47)  | 0.257          | 1.556   | 0.120   |
| Other                      | 0.027        | 1.03 (0.83–1.27)  | 0.107          | 0.254   | 0.799   |
| Hormone receptor status    |              |                   |                |         |         |
| Her2 receptor              | −0.136       | 0.87 (0.78–0.98)  | 0.057          | −2.376  | 0.017   |
| Progestosterone receptor positive | 0.060       | 1.06 (0.98–1.15)  | 0.040          | 1.506   | 0.132   |
| Estrogen receptor positive | −0.063       | 0.94 (0.84–1.05)  | 0.054          | −1.148  | 0.251   |
| Triple negative            | 0.678        | 1.97 (1.53–2.54)  | 0.129          | 5.25    | <0.001  |
| Patient history            |              |                   |                |         |         |
| No history of disease      | NA           | 1.00 (reference)  | NA             | NA      | NA      |
| Non-oncological history    | 0.354        | 1.42 (1.23–1.64)  | 0.073          | 4.824   | <0.001  |
| Oncological history        | 0.086        | 1.09 (0.72–1.64)  | 0.21           | 0.409   | 0.683   |
| Tumor stage                |              |                   |                |         |         |
| Stage I tumor              | NA           | 1.00 (reference)  | NA             | NA      | NA      |
| Stage II tumor             | −0.609       | 0.54 (0.51–0.58)  | 0.032          | −18.999 | <0.001  |

OR odds ratio, CI confidence interval, SES socioeconomic status, ILC invasive lobular carcinoma, NA not applicable, NAN not a number
Table 4 Differences between BCT and mastectomy of new-onset breast cancer patients

|                                | BCT n = 65,888 | Mastectomy n = 32,559 | p value |
|--------------------------------|----------------|-----------------------|---------|
| Age in years, mean (SD)        |                |                       |         |
|                               | 60.4 (11.3)    | 60.7 (14.7)           | 0.001   |
| Age groups                     |                |                       |         |
| Under 40 years, N (%)          | 2155 (48.1%)   | 2321 (51.9%)          |         |
| 40–50 years, N (%)             | 9510 (61.2%)   | 6028 (38.8%)          |         |
| 50–75 years, N (%)             | 48,393 (73.3%) | 17,620 (26.7%)        |         |
| Over 75 years, N (%)           | 5830 (46.9%)   | 6590 (53.1%)          |         |
| Socioeconomic status           |                |                       | < 0.001 |
| 0–9%, N (%)                    | 6067 (64.1%)   | 3398 (35.9%)          |         |
| 10–20%, N (%)                  | 6290 (64.8%)   | 3410 (35.2%)          |         |
| 20–30%, N (%)                  | 6270 (65.4%)   | 3318 (34.6%)          |         |
| 30–40%, N (%)                  | 6448 (66.7%)   | 3214 (33.3%)          |         |
| 40–50%, N (%)                  | 6689 (67.5%)   | 3223 (32.5%)          |         |
| 50–60%, N (%)                  | 6466 (67.4%)   | 3121 (32.6%)          |         |
| 60–70%, N (%)                  | 6558 (67.7%)   | 3130 (32.3%)          |         |
| 70–80%, N (%)                  | 6840 (68.0%)   | 3216 (32.0%)          |         |
| 80–90%, N (%)                  | 7075 (69.4%)   | 3124 (30.6%)          |         |
| 90–100%, N (%)                 | 7185 (67.8%)   | 3405 (32.2%)          |         |
| Tumor stage                    |                |                       | < 0.001 |
| Stage I, N (%)                 | 45,920 (78.3%) | 12,697 (21.7%)        |         |
| Stage II, N (%)                | 19,968 (50.1%) | 19,862 (49.9%)        |         |
| Medical history                |                |                       | < 0.001 |
| No medical history, N (%)      | 61,375 (67.3%) | 29,766 (32.7%)        |         |
| Positive non-oncological medical history, N (%) | 4372 (63.2%) | 2546 (36.8%) |         |
| Positive oncological medical history, N (%) | 141 (36.3%)   | 247 (63.7%)           |         |
| Hormone receptor status        |                |                       |         |
| Her2receptor negative, N (%)   | 59,057 (67.8%) | 28,008 (32.2%)        | < 0.001 |
| Progestrone receptor positive, N (%) | 45,924 (68.4%) | 21,265 (31.6%) |         |
| Estrogen receptor positive, N (%) | 55,295 (68.0%) | 26,028 (32.0%) |         |
| Triple negative, N (%)         | 2076 (55.3%)   | 1681 (44.7%)          | < 0.001 |
| Tumor grade                    |                |                       | < 0.001 |
| Low grade, N (%)               | 18,762 (75.7%) | 6014 (24.3%)          |         |
| Intermediate grade, N (%)      | 31,109 (65.5%) | 16,415 (34.5%)        |         |
| High grade, N (%)              | 16,017 (61.3%) | 10,130 (38.7%)        |         |
| Histological tumor type        |                |                       | < 0.001 |
| No special type, N (%)         | 55,100 (69.3%) | 24,360 (30.7%)        |         |
| ILC, N (%)                     | 6192 (53.7%)   | 5344 (46.3%)          |         |
| Both, N (%)                    | 1560 (51.3%)   | 1481 (48.7%)          |         |
| Mucinous, N (%)                | 1200 (68.3%)   | 556 (31.7%)           |         |
| Medullary, N (%)               | 399 (67.2%)    | 195 (32.8%)           |         |
| Tubular, N (%)                 | 750 (83.5%)    | 148 (16.5%)           |         |
| Other, N (%)                   | 687 (59.1%)    | 475 (40.9%)           |         |
| Neo-adjuvant therapy, N (%)    | 7940 (61.9%)   | 4893 (38.1%)          | < 0.001 |
| Adjuvant therapy, N (%)        | 64,576 (77%)   | 19,337 (23%)          | < 0.001 |
| Detected during screening      | 31,574 (47.9%) | 7796 (23.9%)          | < 0.001 |
| Hospital volume                |                |                       | < 0.001 |
| Low volume                     | 5825 (63.6%)   | 3341 (36.4%)          |         |
| Average volume                 | 15,876 (65.3%) | 8426 (34.7%)          |         |
| High volume                    | 44,187 (68%)   | 20,792 (32%)          |         |
Table 4 (continued)

| Year of diagnosis | BCT n = 65,888 | Mastectomy n = 32,559 | p value |
|-------------------|----------------|------------------------|---------|
| 2011, N (%)       | 7411 (62.2%)   | 4497 (37.8%)           | <0.001  |
| 2012, N (%)       | 7754 (63.7%)   | 4426 (36.3%)           |         |
| 2013, N (%)       | 7943 (64.6%)   | 4347 (35.4%)           |         |
| 2014, N (%)       | 8103 (65.7%)   | 4229 (34.3%)           |         |
| 2015, N (%)       | 8178 (66.3%)   | 4151 (33.7%)           |         |
| 2016, N (%)       | 8602 (69.8%)   | 3722 (30.2%)           |         |
| 2017, N (%)       | 9009 (70.9%)   | 3691 (29.1%)           |         |
| 2018, N (%)       | 8888 (71.8%)   | 3496 (28.2%)           |         |

BCT breast conserving therapy, N number, SD standard deviation, ILC invasive lobular carcinoma

Table 5 Multivariate regression analysis factors influencing the likelihood of undergoing mastectomy compared BCT

| Parameter                               | Estimate (β) | OR (95% CI)      | Standard error | Z value | p value |
|-----------------------------------------|--------------|------------------|----------------|---------|---------|
| SES (per 10% stratum)                  | −0.023       | 0.98 (0.97–0.98) | 0.003          | −9.013  | <0.001  |
| Age (years)                             | 0.004        | 1.00 (1.00–1.01) | 0.001          | 7.758   | <0.001  |
| Year of surgery                         | −0.073       | 0.93 (0.92–0.94) | 0.003          | −22.659 | <0.001  |
| Hospital volume                         |              |                  |                |         |         |
| Small volume                            | NA           | 1.00 (reference) | NA             | NA      | NA      |
| Average volume                          | 0.009        | 1.01 (0.96–1.06) | 0.027          | 0.323   | 0.747   |
| Large volume                            | −0.111       | 0.90 (0.85–0.94) | 0.025          | −4.415  | <0.001  |
| Tumor grade                             |              |                  |                |         |         |
| Low grade                               | NA           | 1.00 (reference) | NA             | NA      | NA      |
| Intermediate grade                      | 0.190        | 1.21 (1.16–1.26) | 0.019          | 9.885   | <0.001  |
| High grade                              | 0.270        | 1.31 (1.25–1.37) | 0.023          | 11.649  | <0.001  |
| Histological subtype                    |              |                  |                |         |         |
| Ductal carcinoma                        | NA           | 1.00 (reference) | NA             | NA      | NA      |
| ILC                                     | 0.625        | 1.87 (1.79–1.95) | 0.022          | 28.307  | <0.001  |
| Both                                    | 0.836        | 2.31 (2.13–2.49) | 0.039          | 21.172  | <0.001  |
| Mucinous                                | 0.07         | 1.07 (0.96–1.19) | 0.055          | 1.271   | 0.204   |
| Medullary                               | −0.055       | 0.95 (0.79–1.14) | 0.093          | −0.588  | 0.556   |
| Tubular                                 | −0.193       | 0.82 (0.69–0.99) | 0.093          | −2.083  | 0.037   |
| Other                                   | 0.271        | 1.31 (1.16–1.49) | 0.064          | 4.217   | <0.001  |
| Hormone receptor status                 |              |                  |                |         |         |
| Her2 receptor negative                  | −0.128       | 0.88 (0.83–0.93) | 0.027          | −4.775  | <0.001  |
| Progesterone receptor positive          | 0.019        | 1.02 (0.98–1.06) | 0.020          | 0.928   | 0.353   |
| Estrogen receptor positive              | 0.002        | 1.00 (0.95–1.06) | 0.028          | 0.058   | 0.954   |
| Triple negative                         | 0.171        | 1.19 (1.08–1.30) | 0.047          | 3.614   | <0.001  |
| Patient medical history                 |              |                  |                |         |         |
| History of disease                      | NA           | 1.00 (reference) | NA             | NA      | NA      |
| Non-oncological medical history         | 0.258        | 1.29 (1.23–1.37) | 0.028          | 9.339   | <0.001  |
| Oncological medical history             | 1.612        | 5.01 (4.01–6.26) | 0.114          | 14.198  | <0.001  |
| Tumor stage                             |              |                  |                |         |         |
| Stage I tumor                           | NA           | 1.00 (reference) | NA             | NA      | NA      |
| Stage II tumor                          | 1.231        | 3.42 (3.33–3.53) | 0.015          | 82.180  | <0.001  |

NA not applicable, OR odds ratio, CI confidence interval, SES socioeconomic status, ILC invasive lobular carcinoma
a factor influencing the immediate breast reconstruction and is easier to organize in a hospital with a large volume [29, 34]. Additionally, reasons for these differences can be the preference of the clinician, unequal spread of SES within the Netherlands, age of patient, tumor grade, tumor stage, and hormone receptor status [7, 8]. Furthermore, a recent study showed that breast cancer patients with high SES are more likely to undergo postmastectomy reconstruction than their lower SES counterparts [29].

The present study has some limitations. Other factors, which are not recorded in the NCR, may also be determinants of surgery type, such as race, ethnicity, health literacy, social environment, language, internet access, and religion. However, these factors are known to be closely linked to SES [9, 35, 36]. Nevertheless, more research is warranted to study the possible effects of cultural background on whether patients are given the same choices regarding breast cancer treatment when there is equal access to healthcare. Additionally, NCR does not record co-morbidities, which could also affect the therapeutic choice on whether or not to operate stage I or II breast cancer patients. Secondly, however, the current study does show that higher SES breast cancer patients are more likely to undergo BCT. The NCR does not have information about how well-informed patients are about their treatment options and if and to what extent shared decision making took place. Therefore, it would be interesting to study whether there also exist differences in information provision to women diagnosed with breast cancer regarding treatment options (non-surgical treatment, BCT, or mastectomy) between hospitals and/or regions in the Netherlands and whether this is influenced by patients’ SES or SES related factors. Moreover, maybe less access to patient information (due to, e.g., language barrier, illiteracy, less access to internet) might contribute to the fact that patients with lower SES are less likely to undergo BCT when operated.

In conclusion, the current study shows that even in a country with equal access to healthcare, stage I or II breast cancer patients with lower SES were less likely to undergo BCT. Age and tumor stage, but not SES, were associated with undergoing surgery-or-not.

Acknowledgements The authors thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. Additionally, they would like to thank Trienika Luth for translating postal codes into SES.

Declarations

Conflict of interest None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper. It is specifically state that “No Competing interests are at stake and there is No Conflict of Interest” with other people or organizations that could inappropriately influence or bias the content of the paper.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
2. Vondeling GT, Menezes GL, Dwortsin EP, Jansman FGA, Konings IR, Postma MJ et al (2018) Burden of early, advanced and metastatic breast cancer in The Netherlands. BMC Cancer 18(1):262–263
3. Koleva-Kolarova RG, Daszczyk AM, de Jonge C, Abu Hantash MK, Zhan ZZ, Postema EJ et al (2018) A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. Maturitas 109:81–88
4. Agarwal S, Pappas I, Neumayer L, Kokeny K, Agarwal J (2014) Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 149(3):267–274
5. Hartmann-Johnsen OJ, Karesen R, Schlichting E, Nygard JF (2015) Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 22(12):3836–3845
6. van Maaren MC, de Munk L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC et al (2016) 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol 17(8):1158–1170
7. van Maaren MC, Strobbe LJA, Koppert LB, Poortmans PMP, Siesling S (2018) Nationwide population-based study of trends and regional variation in breast-conserving treatment for breast cancer. Br J Surg 105(13):1768–1777
8. Sociaal cultureel planbureau. Regional differences in socioeconomic status in the Netherlands [website in Dutch]. Available from: https://www.volksgezondheidenzorg.info/onderwerp/socialeconomische-status/regionaal-internationaal/regionaal#node-socialeconomische-status
9. Adler NE, Boyce T, Chesney MA, Cohen S, Folkman S, Kahn RL et al (1994) Socioeconomic status and health. The challenge of the gradient. Am Psychol 49(1):15–24
10. Laaksonen M, Prattala R, Lahelma E (2003) Sociodemographic determinants of multiple unhealthy behaviours. Scand J Public Health 31(1):37–43
11. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD et al (2009) Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: national longitudinal mortality study. Cancer Causes Control 20(4):417–435
12. Dohrenwend BP, Levai I, Shrot PE, Schwartz S, Naveh G, Link BG et al (1992) Socioeconomic status and psychiatric disorders: the causation-selection issue. Science 255(5047):946–952
13. Psaltopoulou T, Hatzis G, Papageorgiou N, Androulakis E, Briassoulis A, Tousoulis D (2017) Socioeconomic status and risk
factors for cardiovascular disease: impact of dietary mediators. Hell J Cardiol 58(1):32–42
14. Saydah S, Lochner K (2010) Socioeconomic status and risk of diabetes-related mortality in the U.S. Public Health Rep 125(3):377–388
15. Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H (2018) Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: a systematic review. Clin Breast Cancer 18(4):e539–e554
16. van den Broek-Altenburg EM, Atherly AJ (2020) The relation between selective contracting and healthcare expenditures in private health insurance plans in the United States. Health Policy 124(2):174–182
17. Bhat S, Orucovic A, Woody C, Heidel RE, Bell JL (2017) Evolving trends and influencing factors in mastectomy decisions. Am Surg 83(3):233–238
18. Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P (2017) Disparities in the local management of breast cancer in the US according to health insurance status. Breast J 23(2):169–176
19. Norredam M, Groenvold M, Petersen JH, Krasnik A (1998) Effect of social class on tumour size at diagnosis and surgical treatment in Danish women with breast cancer. Soc Sci Med 47(11):1659–1663
20. van Weel C, Knottnerus JA, van Schayck OCP (2020) Managing costs and access to healthcare in the Netherlands: impact on primary care. BMJ 369:m1181
21. Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P (2017) Disparities in the local management of breast cancer in the US according to health insurance status. Breast J 23(2):169–176
22. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93(9):1046–1052
23. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410
24. Lagendijk M, van Maaren MC, Saadatmand S, Stroobbe LJA, Poortmans PMP, Koppert LB et al (2018) Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. Int J Cancer 142(1):165–175
25. de Ligt KM, van Bommel ACM, Schreuder K, Maduro JH, Vranken Peeters MTFD, Mureau MAM et al (2018) The effect of being informed on receiving immediate breast reconstruction in breast cancer patients. Eur J Surg Oncol 44(5):717–724
26. Beaufait-Jones BK, Lavage DR, Snyder JW, Moore JH, Pendergrass SA, Bauer CR (2018) Characterizing and managing missing structured data in electronic health records: data analysis. JMIR Med Inform 6(1):e11
27. Zhang Z (2016) Multiple imputation with multivariate imputation by chained equation (MICE) package. Ann Transl Med 4(2):30–58
28. van Maaren MC, le Cessie S, Stroobbe LJA, Groothuis-Oudshoorn CGM, Poortmans PMP, Siesling S (2019) Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival. J Cancer Res Clin Oncol 145(6):1485–1493
29. Filipe MD, Siesling S, Vriens MR, van Diest PJ, Witkamp AJ, Mureau MAM (2020) Socioeconomic status significantly contributes to the likelihood of immediate postmastectomy breast reconstruction in the Netherlands: a nationwide study. Eur J Surg Oncol 47(2):245–250
30. van Maaren MC, de Munck L, Jobsen JJ, Poortmans P, de Bock GH, Siesling S et al (2016) Breast-conserving therapy versus mastectomy in T1–2N2 stage breast cancer: a population-based study on 10-year overall, relative, and distant metastasis-free survival in 3071 patients. Breast Cancer Res Treat 160(3):511–521
31. Schreuder K, van Bommel ACM, de Ligt KM, Maduro JH, Vranken Peeters MTFD, Mureau MAM et al (2017) Hospital organizational factors affect the use of immediate breast reconstruction after mastectomy for breast cancer in the Netherlands. The Breast 34:96–102
32. Ridgeway CL (2014) Why status matters for inequality. Am Sociol Rev 79(1):1–16. https://doi.org/10.1177/0003122413515997
33. Berger J, Norman RZ, Balkwell JW, Smith RF (1992) Status inconsistency in task situations: a test of four status processing principles. Am Sociol Rev 57(6):843
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.